Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting-edge solutions based on its patented FluidFM® technology.
At the heart of this technology are the hollow FluidFM Probes – the Micropipette, Nanopipette, and the Nanosyringe – specifically designed to offer a wide range of unique applications for single-cell manipulation in biology research. Cytosurge's current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system.

Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, contributing to human well-being through advancements in single-cell technologies. As the partner of choice for precision gene engineering cell line manufacturing, Cytosurge enables next-generation biologic production and cell and gene therapy treatments, empowering people to live longer and healthier lives.
Cytosurge implements advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and the manufacturing of high-precision gene-engineered cell lines. With a unique single-cell workflow and dynamic gene expression analytics, Cytosurge manufactures advanced gene-engineered cell lines, empowering next-generation treatments to benefit human well-being.

Biotechnology

Cytosurge AG

Pascal Behr

Dr. Lorenz Malär

Wey Zhu

Tobias Beyer

Stephan Jud

Simon Egli

Lorenz Malär

Bernard Wasem

Leadership Team

Research and Development

Sales and Business Development

Engineering and Technical

Human Resources and Finance

Marketing and Product Management Team